Vaccines: focus on adults - Summa Health System
Vaccines: focus on adults - Summa Health System
Vaccines: focus on adults - Summa Health System
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
US Influenza <str<strong>on</strong>g>Vaccines</str<strong>on</strong>g>• TIV: ‘Killed’, injectable “All comers” 6 m<strong>on</strong>ths and older• TIV Intradermal• Approved May 2011 for 18-64 years [smaller needle]• LAIV: Live-attenuated, cold-adapted nasal (CANNOT replicate at bodytemperature)-nasal spray• very minimal viral shedding; OK to give to nurses unless taking care ofseverely immunocompromised patients (e.g. Stem cell transplant)• Indicated <strong>on</strong>ly for healthy people 2-50 years• High-Dose TIV for 65+ populati<strong>on</strong> * [first available 2010-11]• Same producti<strong>on</strong> process as TIV; higher Ag dose• Seroc<strong>on</strong>versi<strong>on</strong>, seroprotecti<strong>on</strong> rates ≥ TIV for A, B strains• Superiority criteria for A, N<strong>on</strong>-inferiority for B strain• Local reacti<strong>on</strong>s more frequent but classified as mild• ‘Real world’ efficacy data not published to dateTIV, trivalent inactivated vaccine*Falsey AR et.al. J Infect Dis. 2009;200:172-180.
Change language